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Cervical carcinoma is a major gynaecological malignancy and
human papillomavirus (HPV) has been suggested to be involved in
the aetiology of this carcinoma. HPV types, such as type 16, 18,
31, 33, 35, 39, 45, 51, 52, 56 and 58, have been found in cervical
carcinoma (Yoshikawa et al, 1991; Lorincz et al, 1992). These
cervical carcinoma-associated HPVs encode two viral oncogenes,
E6 and E7. The coordinated expression of E6 and E7 has been
shown to transform rodent cells and immortalize primary human
keratinocytes (Kanda et al, 1988; Munger et al, 1989a). The E6
and E7 proteins of high-risk HPVs have been demonstrated to be
able to associate with the products of p53 and retinoblastoma
susceptibility (Rb) genes, respectively, and inactivate the functions
of these tumour suppressor proteins (Munger et al, 1989b;
Werness et al, 1990). The E6 protein exerts rapid degradation of
p53, in corporation with E6-associated protein (E6-AP), via
ubiquitin-mediated proteolysis pathway (Scheffner et al, 1990;
Huibregtse et al, 1993). The E7 protein mediates the release of the
E2F transcription factor from pRb—E2F complex (Nevins, 1992).
Mutational analysis of HPV 16 E6 protein revealed that a certain
level of the activity to degrade p53 is required for E6 to manifest
its transforming function (Nakagawa et al, 1995).
The p53 mutations are the most frequent genetic abnormalities
found in a wide variety of human malignant tumours (Harris,
1993). Once DNA damage occurs, p53 protein is induced and
arrests cells in the G1 phase to enhance DNA repair (Kuerbitz et
al, 1992), or triggers apoptosis following DNA damage (Lowe et
al, 1993). These functions of p53 protein are important to maintain
the genomic integrity. Mutant p53 protein are devoid of these
functions, because they lose the ability of DNA contact or destabi-
lize the structure of the core domain (Cho et al, 1994). In this way,
once p53 is mutated, DNA damage is fixed and subsequent genetic
rearrangement progress which may be putative mechanisms to
initiate cancer. Thus far, exceptionally low prevalence (0—6%) of
the p53 mutations have been documented in cervical carcinomas
(Fujita et al, 1992; Choo and Chong, 1993; Helland et al, 1993;
Paquette et al, 1993; Miwa et al, 1995). The p53 protein in cervical
carcinoma is thought to be inactivated presumably due to complex
formation with HPV E6 oncoprotein. Although Crook et al
initially postulated that p53 mutations were confined to the HPV-
negative cervical carcinomas (Crook et al, 1991; Crook and
Vousden, 1992), several recent studies implicated that p53 muta-
tion was a very rare event and the occurrence was not strictly
correlated with HPV status in primary cervical carcinomas (Fujita
et al, 1992; Choo and Chong, 1993; Helland et al, 1993; Paquette
et al, 1993; Miwa et al, 1995). It has been also shown that p53
mutants identified in the HPV-positive anogenital cancers exhibit
increased resistance to HPV E6-directed degradation, suggesting
that mutation of p53 may play a role in the progression of the
HPV-positive cervical cancer (Crook and Vousden, 1992).
Recently, p53 mutation frequency in vulvar carcinomas is
reported to be much higher compared with cervical carcinoma by
24%, (Lee et al, 1994), 53% (Milde-Langosch et al, 1995) and
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Correspondence to: H Yoshikawa53% (Kagie et al, 1997). Vulvar cancer generally occurs in women
over ten years older than women with cervical cancer, with a peak
incidence between 65 and 75 years old (Langosch et al, 1995). The
incidence of high-risk HPVs, such as types 16 and 18, is lower in
vulvar cancers than in cervical cancers (Nagano et al, 1996), the
finding suggesting that mutation of p53 together with HPV may be
involved in the carcinogenesis of the vulva.
In our previous study, the incidence of high-risk HPV as
compared to that of intermediate-risk HPV in cervical cancer
showed that intermediate-risk HPV occurrence was higher in
patients 60 years old or older (Nakagawa et al, 1996). Taken
together with data observed in vulvar cancer, we hypothesized that
p53 mutation might be involved in the carcinogenesis of cervical
cancer in older patients. To address this, we examined HPV infec-
tion and the mutation of p53 gene in 46 primary cervical carci-
nomas in women 60 years old or older.
MATERIALS AND METHODS
Patients
Forty-six cervical carcinoma patients 60 years old or older who
were treated during the period from 1987 to 1994 at the University
of Tokyo Hospital, the Tokyo Metropolitan Komagome Hospital
and the National Cancer Center Hospital were enrolled in this
study. Informed consent regarding the use of tissue specimens for
research was obtained from all patients. Clinical information was
obtained by chart review. Of the 46 patients, 41 had squamous cell
carcinoma (keratinizing type, ten; large cell non-keratinizing
type, 31) and five had adenocarcinoma (endocervical type, four;
endometrioid type, one). Adenosquamous carcinoma, variant
types of squamous cell carcinoma, such as verrucous and condylo-
matous carcinomas etc., and those of adenocarcinoma, such as
clear cell and serous adenocarcinomas and adenoma malignum
etc., were not included in these cases. The average age at clinical
onset was 71 years with a range of 60—96 years. On the basis of the
International Federation of Gynecology and Obstetrics (FIGO)
criteria, 12 women had Stage I, 18 Stage II, 15 Stage III and 1
Stage IV.
Detection and typing of HPV
The tissue specimens diagnosed histologically as cervical cancer
were frozen at —80°C immediately after excision and stored until
the assay for detection of HPV. The cellular DNA was extracted by
standard sodium dodecyl sulphate (SDS)-proteinase K procedure.
Polymerase chain reaction (PCR) for the L1 region was done
by a partly modified method previously described by Yoshikawa
et al (1991). We used the consensus L1 primers L1C1
(5¢-CGTAAACGTTTTCCCTATTTTTTT-3¢) (1 mM), L1C2 (5¢-
TACCCTAAATACTCTGTATTG-3¢) (0.5 mM) and L1C2M (5¢-
TACCCTAAATACCCTATATTG-3¢) (0.5 mM) for the PCR. Other
conditions of PCR were described elsewhere by Yoshikawa et al.
Briefly, the PCR protocol was 40 cycles, and each cycle consisted
of 1.5 min denaturation (95°C), 1.5 min annealing (48°C) and
2 min extension (70°C). One-tenth of the reaction was electro-
phoresed on 4% agarose gel and stained with ethidium bromide.
HPV types were identified on the basis of the restriction fragment
length polymorphisms (RELP). The initial typing of amplified
HPV DNA fragments was performed by digestion with DdeI and
RsaI, and then confirmed by digestion with at least three enzymes
selected from AccI, AluI, BstXI, FokI, HaeIII, HinfI, KpnI, MaeI,
MaeIII, PstI and XbaI. The PCR-based assay (L1-PCR) can type at
least 26 registered genital HPVs including types 6, 11, 16, 18, 30,
31, 33, 34, 35, 39, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61,
66, 68 and 70, as described previously. This PCR system can detect
0.01 pg of all these types of HPV DNA, except for HPV type 34, 42
and 55 DNAs, in 0.1 mg of the cellular DNA. We used b-actin gene
amplification as control in order to rule out false negative results
for samples in which HPV DNA was not detected.
We classified these HPVs into high-risk HPVs (types 16 and 18)
and intermediate-risk HPVs (other cervical cancer-associated
types) basically based on Lorincz￿s classification (Lorincz et al,
1992). HPV type 68, which was identified later, was regarded as a
member of intermediate-risk HPV.
PCR–SSCP and sequence analysis of p53 gene
The p53 protein has a transactivation domain at its N-terminal, a
sequence-specific DNA-binding domain at its central region, and a
tetramerization domain at its C-terminal. The majority of the
missense mutations occur in the central DNA-binding domain,
especially in the conserved regions across species, that are exon
5—8 (Cho et al, 1994). Mutation of the p53 gene in exon 5—8 was
analysed by PCR-based single-strand conformation polymorphism
(SSCP) and DNA sequencing technique (Naito et al, 1992).
The primers used in this study to amplify the p53 gene PCR
were as follows:
exon 5 — sense primer: 5¢-TGTTCACTTGTGCCCTGACT-3¢
antisense primer: 5¢-CAGCCCTGTCGTCTCTCCAG-3¢
exon 6 — sense primer: 5¢-GCCTCTGATTCCTCACTGAT-3¢
antisense primer: 5¢-TTAACCCCTCCTCCCAGAGA-3¢
exon 7 — sense primer: 5¢-ACTGGCCTCATCTTGGGCCT-3¢
antisense primer: 5¢-TGTGCAGGGTGGCAAGTGGC-3¢
axon 8 — sense primer: 5¢-TAAATGGGACAGGTAGGACC-3¢
antisense primer; 5¢-TCCACCGCTTCTTGTCCTGC-3¢
First, PCR protocol was 35 cycles, and each cycle consisted of
30 s denaturation (94°C), 30 s annealing (60°C) and 30 s extension
(72°C) for exon 5 and exon 7. For exon 6 and exon 8, annealing
temperature was changed to 55°C; other conditions were the same
as for the protocol for the amplification of the exon 5 and exon 7.
The first PCR contained the template DNA (0.2 mg), primers
(0.1 mM), and Taq-polymerase (1-unit, Boehringer Mannheim).
PCR buffer supplied by the manufacturer was used. The second
PCR contained the product of the first PCR (1 ml), a-32p dCTP
(0.5 ml) and Taq-polymerase (0.5-unit). Second PCR protocol was
10—15 cycles, and each cycle consisted of 30 s denaturation (94°C),
30 s annealing (62°C) and 60 s extension (72°C) for exon 5 and
exon 7. For exon 6 and exon 8, only the annealing temperature was
changed to 55°C. The second PCR product was mixed with loading
dye (95% formamide, 0.05% bromophenol blue, 0.05% xylene
cyanol, 20 mM EDTA), and heat denatured at 80°C for 10 min.
Two ml of the PCR product with loading dye was loaded onto 5%
polyacrylamide gel containing 5% glycerol, and electrophoresed at
a constant voltage of 35 W at 25°C for 3 h. The gel was dried with
vacuum, and autoradiographed for 1—2 days at room temperature.
The first PCR product of the case which showed the mobility
shift by the PCR—SSCP method was subcloned to the T-vector
(Invitrogen). The sequence of the cloned plasmid was determined
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Biosystems as recommended by the manufacturer, or the sequence
of the PCR products was directly determined by using the Taq dye
deoxy terminator cycle sequencing method (Figure 2). We used
DNA extracted from normal cervical tissue with normal p53 and a
tissue specimen of colon adenocarcinoma with p53 mutation as
negative and positive controls, respectively.
Immunohistochemistry of p53
Overexpression of p53 was analysed by immunohistochemistry
(van Ravenswaay Classen et al, 1992). Sections of 5 mm were
cut from paraffin-embedded tissues and dewaxed in xylene.
Endogeneous peroxidase was blocked in 0.3% H2O2 methanol.
Non-specific binding was blocked with the serum-free protein
(CSA system, DAKO, Japan). Tissue sections were incubated for
15 min at room temperature with the anti-human p53 monoclonal
antibody DO-7 (DAKO, Japan) diluted 1:100 in phosphate
buffered saline (PBS), and then the secondary antibody,
biotinylated rabbit antimouse immunoglobulin, in the humiliated
chamber. After incubation with the streptavidin—biotin—peroxidase
complex, the nuclei were visualized with diamino—benzidine. The
nuclei was counterstained with Mayer haematoxylin. We used
normal cervical tissue with normal p53 and a tissue specimen of
colon adenocarcinoma with p53 mutation and a high expression of
p53 as negative and positive controls, respectively.
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Table 1 HPV type, clinical data and p53 mutation
p53 status
Case number HPV type Age Histology Stage Amino acid Immunohistochemistry
1 16 60 SCC Ib WT ND
2 16 60 SCC IIIb WT ND
3 16 60 SCC IIIb WT ND
4 16 62 SCC Ib WT ND
5 16 63 SCC IIb WT ND
6 16 63 SCC IIb WT ND
7 16 64 SCC IIb WT Negative
8 16 64 SCC IIb WT ND
9 16 66 SCC IIIb 131 Asn ® Asn Positive
133 Met ® Ile
10 16 67 SCC IIb WT ND
11 16 69 SCC IIb WT ND
12 16 71 SCC IIIb WT Negative
13 16 72 SCC IIIb WT ND
14 16 72 AC IIIb WT ND
15 16 78 SCC IIa WT ND
16 18 62 AC Ib WT ND
17 18 68 SCC Ib WT Negative
18 31 61 SCC Ib WT ND
19 33 64 SCC IIa WT ND
20 33 77 SCC IIIb WT ND
21 33 82 SCC IIb WT Negative
22 35 85 SCC IIIb WT ND
23 35 85 SCC IIIb WT ND
24 51 84 SCC IVa WT ND
25 52 60 SCC Ib WT ND
26 52 60 SCC IIIa WT Negative
27 52 61 SCC IIb 248 Arg ® Gln Positive
28 52 62 SCC Ib WT ND
29 52 65 SCC Ib WT ND
30 52 69 SCC IIa WT ND
31 52 73 SCC Ib WT Negative
32 52 74 SCC IIIb WT ND
33 52 81 SCC IIb 181 Arg ® Cys Positive
34 52 84 AC Ib WT ND
35 52 96 SCC IIIb WT ND
36 58 60 SCC IIb WT ND
37 58 62 SCC IIb WT Negative
38 58 65 SCC IIa WT ND
39 58 67 SCC IIb 248 Arg ® Gln Positive
40 58 72 SCC Ib WT ND
41 58 75 SCC Ib 189 Ala ® Val Positive
42 58 78 AC IIIb WT ND
43 58 79 SCC IIIb WT ND
44 68 69 SCC IIa WT ND
45 Negative 82 AC IIb WT ND
46 Negative 90 SCC IIIb WT ND
SCC, squamous cell carcinoma; AC, adenocarcinoma; WT, wild-type; ND, not done.Statistical analysis
The statistical methods used in this study were c2 method and
ANOVA approach. All statistical analyses were done with
StatView 4.11.
RESULTS
HPV types detected in cervical carcinoma in women 60
years old or older
HPV DNA was detected in 44 out of 46 (96%) cervical cancer
specimens. HPV type 16 was the most frequently found HPV type
(15 cases), followed by type 52 (11 cases) and type 58 (eight
cases) (Table 1). HPV type 18, the second most common HPV
type in cervical cancer (Yoshikawa et al, 1991; Lorincz et al,
1992), was found only in two cases. Other HPV types found in this
study were HPV type 31 (one case), type 33 (three cases), type 35
(two cases), type 51 (one case) and type 68 (one case). The inci-
dence of the high-risk HPVs (types 16 and 18) was lower (37%
[17/46]) and that of the intermediate-risk HPVs (HPVs other than
type 16 and 18) was higher (59% [27/46]) compared with HPV
type distribution hitherto described (Yoshikawa et al, 1991;
Lorincz et al, 1992).
PCR–SSCP and sequence analysis of p53 gene
The PCR—SSCP analysis revealed the abnormal mobility shifts of
p53 gene in five of 46 (11%) cases: two cases in the exon 5, one
case in the exon 6 and two cases in the exon 7 (Figure 1, Table 1).
The subsequent nucleotide sequencing analysis revealed a
missense mutation in the five cases, except one case which
contained a silent mutation and a missense at the different codons
(Figure 2). The six-point mutations of the p53 gene were detected
in five HPV-positive cases: one for HPV 16, two HPV for 52, and
two for HPV 58. No mutations of the p53 gene were detected in
two HPV-negative cases. Mutations of the p53 gene revealed by
sequence analysis were as follows: an AAC—AAT transition in
codon 131, an ATG—ATA transition in codon 133, a CGC—TGC
transition in codon 181, a GCC—GTC transition in codon 189, two
CGG—CAG transitions in codon 248. An AAC—AAT transition in
codon 131 and an ATG—ATA transition in codon 133 were
detected in one case (Figure 2).
The histology of the five cases with p53 mutation was squa-
mous cell carcinoma and we could not detect any p53 mutation in
five cases with adenocarcinoma. There were no significant differ-
ences in patient age, clinical stage and lymph node metastasis
between the cases with and without p53 mutation (Table 1). The
p53 mutation was more frequently observed in samples with inter-
mediate-risk HPVs (four of 27 samples [15%]) than those with
high-risk HPVs (one of 17 samples [6%]), though statistically not
significant (P = 0.36).
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AB C D
Codon 128 129 130 131 132 133 134 135 136
Amino acid Pro Ala Leu Asn Lys Met Phe Cys Glu
Ile






Figure 1 PCR–SSCP analysis of exons 5, 6 and 7 with the abnormal
mobility shifts. Arrowheads indicate the abnormally shifted bands.
(A) PCR–SSCP analysis of exon 5 (case 9), (B) PCR–SSCP analysis of
exon 5 (case 33), (C) PCR–SSCP analysis of exon 6 (case 41) and (D)
PCR–SSCP analysis of exon 7 (case 27)
Figure 2 Direct sequencing analysis of PCR product of p53 (exon 5 of case
9). Arrowheads indicate the mutated nucleotides. AAC–AAT transition in
codon 131 results in a silent mutation and ATG–ATA transition in codon 133
results in an isoleucine substitution for methionine
Figure 3 Immunohistochemistry of p53. Immunohistochemistry shows (A)
strong nuclear staining of the carcinoma tissue with p53 mutation in exon 6
(case 41) and (B) negative staining of the carcinoma tissue with normal p53
(case 7)Immunohistochemical analysis of p53
The stability of p53 mutants identified in this study was analysed
by the immunohistochemical staining with p53 monoclonal anti-
body. Strong positive nuclear staining for p53 was observed in all
the five carcinoma tissues with p53 mutation, whereas only weak
or negative staining was observed in seven carcinoma tissues with
normal p53 (Figure 3).
DISCUSSION
In the present study, HPV DNA was found in cervical carcinoma
in 44 out of 46 (96%) elderly women. The higher detection rate of
the HPV DNA suggested that HPV infection plays a key role in the
carcinogenesis of cervical carcinoma even in elderly women. Most
studies to date documented that the detection rate of the HPV type
16 and type 18 has been reported to be approximately 60%,
whereas the intermediate-risk HPV types are thought to be minor
HPV types in cervical carcinoma (Snijders et al, 1990; Lorincz et
al, 1992). We have documented that the incidences of the high- and
intermediate-risk HPVs reported by PCR-based detection in
cervical cancers from Japanese women of all ages were 69% and
27%, respectively (Yoshikawa et al, 1991). These findings are
consistent with data by other Japanese investigators who reported
that the incidences of the high- and intermediate-risk HPVs were
62% and 21%, respectively (Fujinaga et al, 1991). In this regard, it
seems that the incidence of high-risk HPVs (37%) observed in
elderly women is lower and that of intermediate-risk HPVs (59%)
is higher compared with those found in young or middle-aged
women. Observed higher incidence of intermediate-risk HPVs in
elderly women may give rise to the assumption that the duration
from primary HPV infection to the clinical manifestation of
cervical cancer might be longer in intermediate-risk HPVs associ-
ated carcinogenesis.
Point mutation of the p53 gene was detected in five out of 46
(11%) primary cervical carcinomas of elderly age: one of 17
samples (6%) positive for high-risk HPV type and four of 27
samples (15%) positive for intermediate-risk HPV type. The p53
mutation frequency in primary cervical carcinomas has been
reported to be 0—6% (Fujita et al, 1992; Choo and Chong, 1993;
Helland et al, 1993; Paquette et al, 1993; Miwa et al, 1995). The
p53 mutation rate in this study was relatively higher compared
with the previously reported data. It appears probable that the
higher incidence of p53 mutation is a feature of cervical cancer in
elderly women. Interestingly, all p53 mutations were detected in
HPV-positive cases. Among the five cases with p53 mutation, four
cases were positive for intermediate-risk HPV (two HPV52-posi-
tive and two HPV58-positive), suggesting that p53 mutation is
more frequently associated with intermediate-risk HPVs than with
high-risk HPVs. Because the transforming activity of these inter-
mediate-risk HPVs is thought to be lower than that of the high-risk
HPVs (Storey et al, 1988) and p53 inactivation activity of E6
proteins of intermediate-risk HPVs is less efficient than that of
high-risk HPVs (Lechmer and Laimins, 1994), it is conceivable
that mutation of the p53 gene has an auxiliary effect in carcinogen-
esis on the intermediate-risk HPV infected cells.
Mutations of the p53 gene in this study were detected in codons
131, 133, 181, 189 and 248 (Table 1). The p53 mutation in codons
131 and 133 was detected in one case and that in codon 248 in two
cases. In four out of five cases with p53 mutation, the mutation
was detected in conserved regions II (codons 117—142), III
(codons 171—181) and IV (codons 234—258). All five mutated
codons detected in this study are thought to be important for direct
and indirect DNA binding. Codons 131 and 133 reside in the
loop—sheet—helix motif (codons 112—141, 271—274, 278—286) and
codon 248 resides in the L3 loop (codons 236—251). Codon 181
and codon 189 reside in the second large L2 loop (codons
163—195). Most hotspots for mutation occur in the
loop—sheet—helix motif and the large L3 loop, both of which
interact directly with DNA, and in the second large L2 loop, which
is involved in an extensive interaction with the L3 loop (Cho et al,
1994). In particular, codon 248 is one of the mutation hotspots and
9.6% of p53 mutations involve this residue (Cho et al, 1994). The
elimination of DNA binding activity of the mutated p53 may lead
to the loss of its tumour-suppressive function.
Immunohistochemical staining analysis revealed the stable
overexpression of mutant p53 in the HPV-positive cervical carci-
noma with mutated p53 gene. We confirmed the HPV E6 expres-
sion in cancer tissues positive for intermediate-risk HPV as well as
high-risk HPV with simple and sensitive detection of E6 and E7
expression using consensus primer-mediated RT-PCR (data not
shown). The mutant p53 identified in the HPV-positive cervical
carcinoma seems to be resistant to E6-directed degradation in
vivo, in keeping with the previous in vitro analysis (Crook and
Vousden, 1992). There are several studies reporting that mutant
p53 has an oncoprotein-like function (Dittmer et al, 1993).
Therefore, the mutated p53 identified in this study may have a
supportive role in the carcinogenesis of cervical cancer in concert
with HPV.
All p53 mutations identified in this study were classified into
the transition type, which occurs frequently in endogenous muta-
genesis, whereas the transversion type tends to occur by environ-
mental carcinogen (Harris, 1993). It is, therefore, suggested that
the p53 gene mutation in the cervical carcinomas in elderly women
may be caused by endogenous mutagenesis.
In summary, the present study supports the contention that a
relatively higher incidence of intermediate-risk HPV infection and
its coupling with p53 gene mutation in cervical cancer affecting
elderly women, thus implicating intermediate-risk HPV in combi-
nation with p53 mutation, may constitute one pathogenetic factor
in cervical cancer developed in elderly women. Because this study
has a limited capacity to allow a firm conclusion, further studies on
the link between p53 mutation and less potent oncogenic HPV
types are warranted.
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